Jemperli sales reach $644 million as AnaptysBio awaits 2027 FDA decision
AI Summary- AnaptysBio reported Jemperli collaboration sales of $644 million for the first half of 2026.
- Jemperli sales rose 34% year over year in the six months ended June 30, 2026.
- AnaptysBio expects a Q4 2026 or Q1 2027 judgment in its GSK and Tesaro litigation.